SISajida Hussein Ismael

Sajida Hussein Ismael

*This is an algorithmically generated author record based on publicly available information.

Sajida Hussein Ismael has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sustainable quinazoline synthesis over a novel multifunctional CS‑NPs@MWCNT@CuFe₂O₄@Zeolite catalyst

    by Mohamed Abu Shuheil, Sajida Hussein Ismael, Roopashree R, Subhashree Ray, Baraa Mohammed Yaseen, Kavitha V, Renu Sharma, Aashna Sinha, Ahmad Sajjadi


  • Open Access

    The Usage and Limitations of Gene Therapy Versus Stem Cell Therapy for Myotonic Dystrophy Type 1 (DM1): Special Focus on Immune Response

    by Zhainagul Abdirasulovna Abdirasulova, Basim Hanoon Jabbar, Sajida Hussein Ismael, Ahmed M. Hussein, Saad Saleh, Nazarzoda Khusin Nazir

    Muscular dystrophies include myotonic dystrophy (MD). Although there is no cure for this disorder, many treatments can manage symptoms and reduce disease development. Standard pharmacological treatments and rehabilitation methods have largely failed, prompting researchers to investigate stem cell and gene therapy options. This review will discuss gene therapy and stem cell therapy as adjuvant therapies for MD, including their benefits, drawbacks, and timeline for implementation. We searched PubMed, Scopus, Web of Science (WOS), Cochrane Library, and Embase from 1980 to 2024 for preclinical and clinical gene therapy papers for MD using keywords such as "myotonic dystrophy" and "gene therapy." A search for "myotonic dystrophy" and "Stem Cell" yielded studies on stem cell treatment for MD. The initial search found 50 gene therapy and 38 stem cell research articles. Following our exclusion and filtering criteria, we deleted 31 articles on gene therapy and 23 articles on stem cells. We found 19 gene therapy publications and 15 stem cell-based publications. Antisense oligonucleotides (ASO), CRISPR technology, and AAV vectors have become the most popular methods. Induced pluripotent stem cells (iPSCs) and muscle-derived progenitor cells (MuSCs) were important cellular sources for investigation or application. Most research focuses on myotonic dystrophy type I (DM1). It is widely established that AAV vector-induced immune responses can affect the safety and efficacy of genetic therapy. Specific stem cells may also modulate MD patients' immunological responses, improving prognosis. Using cytokines and monoclonal antibodies as adjuvants to treat this complex illness is becoming more common.

  • Open Access

    Glycoprotein G-Based Vaccines for Nipah Virus: Epidemiology, Molecular Insights, Benefits, and Limitations

    by Murzaeva Mariia, Imad Ghanem Qasim, Sajida Hussein Ismael, Zahaa Aldeen Jamal, Abdalfattah Sharad, Hastyar Hama Najmuldeen, Nurila Aryntayeva

    Nipah virus (NiV) is a highly virulent zoonotic pathogen associated with significant mortality rates and limited treatment options, posing a significant public health threat. This review explores the epidemiology, molecular structure, and vaccine development efforts targeting glycoprotein G, a critical component of the virus's entry mechanism. Advances in structural biology and immunogenetics have highlighted the potential of glycoprotein G-based vaccines in preventing NiV infections. Despite promising preclinical results, challenges such as immune evasion, safety concerns, and limited clinical trials persist. Additionally, we examine the benefits of glycoprotein G-based vaccines in enhancing immune responses and preventing viral entry, as well as the limitations posed by genetic diversity and cross-reactivity. This review highlights the critical need for ongoing research to overcome existing challenges and guide future vaccine development efforts against NiV. It further underscores the necessity of innovative approaches in vaccine design to reduce the global burden of NiV infections. Glycoprotein G-based vaccines represent a promising avenue for combating NiV infections. Advances in structural biology, immune system targeting, and delivery system technology are paving the way for more effective vaccines. However, overcoming challenges such as cross-reactivity and safety concerns will require continued innovation and collaboration.